Related Experiment Video
Updated: Jan 30, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Chronic Kidney Disease: A Meta-Analysis
Xiaocheng Cheng1, Qiongwen Hu2, Hanru Zhao3
1Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Insights
Transcatheter aortic valve replacement (TAVR) shows lower early mortality and stroke risk compared to surgical aortic valve replacement (SAVR) in chronic kidney disease (CKD) patients. TAVR also reduces acute kidney injury and transfusion needs, making it a potentially preferred option for CKD patients.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Interventional Cardiology
Background:
- Chronic kidney disease (CKD) is a significant comorbidity in patients undergoing aortic valve replacement.
- Both transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are established treatments for aortic valve stenosis.
- The comparative clinical outcomes of TAVR versus SAVR in the specific population of patients with CKD remain incompletely understood.
Purpose of the Study:
- To conduct a meta-analysis comparing the clinical outcomes of TAVR and SAVR.
- To specifically evaluate these outcomes in patients diagnosed with chronic kidney disease (CKD).
- To assess risks of mortality, stroke, and other complications between TAVR and SAVR in CKD patients.
Main Methods:
- A meta-analysis was performed on 10 observational cohort studies.
- Data were sourced from Medline, Cochrane Library, and Embase databases, covering publications from January 2000 to October 2018.
- Included were 9,619 patients with CKD undergoing aortic valve replacement; random-effects modeling was used for pooled analysis.
Main Results:
- TAVR was associated with significantly lower early all-cause mortality (6.1% vs. 10.2%) and postoperative stroke (1.1% vs. 2.2%) compared to SAVR.
- TAVR demonstrated reduced risks of blood transfusion, infection, and acute kidney injury (AKI), including AKI requiring dialysis.
- Increased pacemaker implantation rates were observed with TAVR, but no significant differences in cardiac tamponade or major vascular damage were found.
Conclusions:
- Transcatheter aortic valve replacement (TAVR) may represent a preferable treatment strategy over surgical aortic valve replacement (SAVR) for patients with chronic kidney disease (CKD).
- The findings suggest potential benefits of TAVR in reducing key adverse events in this vulnerable patient group.
- A large, prospective, randomized controlled trial is recommended to definitively establish the superiority of TAVR in CKD patients.
Objective:
The aim of this meta-analysis was to compare the clinical outcomes of transcatheter aortic valve replacement (TAVR) with those of surgical aortic valve replacement (SAVR) in patients with chronic kidney disease (CKD).
Design:
Meta-analysis of 10 observational studies.
Setting:
Hospital.
Participants:
Patients with CKD (9,619) undergoing aortic valve replacement.
Interventions:
None.
Measurements And Main Results:
The Medline, Cochrane Library, and Embase databases were searched for clinical studies published from January 2000 to October 2018. Studies that fulfilled the predefined inclusion criteria were included. The primary clinical outcomes included early all-cause mortality and postoperative stroke. Random-effects modeling was used to calculate odds ratio (OR) and 95% CI. After a literature search of the major databases, 10 observational cohort studies with a total of 9,619 patients were identified. Pooled analysis indicated that, when compared with SAVR, TAVR was associated with a lower risk of early all-cause mortality (6.1% v 10.2%; OR: 0.71; 95% CI: 0.51-0.98) and stroke (1.1% v 2.2%; OR: 0.53; 95% CI: 0.37-0.75). Although TAVR increased the risk of pacemaker implantation (OR: 2.06; 95% CI: 1.16-3.66), it reduced the risk of blood transfusion (OR: 0.50; 95% CI: 0.39-0.65), infection (OR: 0.30; 95% CI: 0.13-0.70), acute kidney injury (AKI) (OR: 0.46; 95% CI: 0.38-0.55), and AKI requiring dialysis (OR: 0.66; 95% CI: 0.58-0.75). There were not significant differences in the incidence rates of cardiac tamponade (OR: 0.60; 95% CI: 0.26-1.36) and major vascular damage (OR: 1.12; 95% CI: 0.81-1.55) between the 2 groups.
Conclusion:
Transcatheter aortic valve replacement might be a preferable approach to SAVR in patients with CKD. A large, prospective, randomized controlled trial is warranted.
More Related Videos
14:14Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Kidney Transplant II: Surgical Procedure
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...